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Abstract
Background: All obese pregnant women are considered at equal high risk with respect to complications in
pregnancy and birth, and are commonly managed through resource-intensive care pathways. However, the
identification of maternal characteristics associated with normal pregnancy outcomes could assist in the management
of these pregnancies. The present study aims to identify the factors associated with uncomplicated pregnancy and
birth in obese women, and to assess their predictive performance.
Methods: Data form obese women (BMI≥ 30 kg/m2) with singleton pregnancies included in the UPBEAT trial were
used in this analysis. Multivariable logistic regression was used to identify sociodemographic, clinical and biochemical
factors at 15+0 to 18+6 weeks’ gestation associated with uncomplicated pregnancy and birth, defined as delivery of a
term live-born infant without antenatal or labour complications. Predictive performance was assessed using area under
the receiver operating characteristic curve (AUROC). Internal validation and calibration were also performed. Women
were divided into fifths of risk and pregnancy outcomes were compared between groups. Sensitivity, specificity, and
positive and negative predictive values were calculated using the upper fifth as the positive screening group.
Results: Amongst 1409 participants (BMI 36.4, SD 4.8 kg/m2), the prevalence of uncomplicated pregnancy and
birth was 36% (505/1409). Multiparity and increased plasma adiponectin, maternal age, systolic blood pressure
and HbA1c were independently associated with uncomplicated pregnancy and birth. These factors achieved an
AUROC of 0.72 (0.68–0.76) and the model was well calibrated. Prevalence of gestational diabetes, preeclampsia
and other hypertensive disorders, preterm birth, and postpartum haemorrhage decreased whereas spontaneous
vaginal delivery increased across the fifths of increasing predicted risk of uncomplicated pregnancy and birth.
Sensitivity, specificity, and positive and negative predictive values were 38%, 89%, 63% and 74%, respectively. A
simpler model including clinical factors only (no biomarkers) achieved an AUROC of 0.68 (0.65–0.71), with sensitivity,
specificity, and positive and negative predictive values of 31%, 86%, 56% and 69%, respectively.
Conclusion: Clinical factors and biomarkers can be used to help stratify pregnancy and delivery risk amongst obese
pregnant women. Further studies are needed to explore alternative pathways of care for obese women demonstrating
different risk profiles for uncomplicated pregnancy and birth.
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Background
Maternal obesity is associated with increased risk of ma-
ternal and perinatal mortality and morbidity, including
gestational diabetes mellitus (GDM), preeclampsia and
birth complications [1]. In common with global trends of
obesity in the non-pregnant population, the prevalence of
maternal obesity is increasing, with one in four women of
reproductive age in the UK being classed as obese [1, 2].
The NHS costs of care and management of pregnancy
complications in obese women have been estimated at an
additional £1171 (37%) per pregnancy compared to
women of normal body mass index (BMI) [3].
A key strategy of the UK 2016 Maternity Transform-
ation Programme is the evidence-based provision of
antenatal care that recognises different levels of risk of
adverse outcomes between different groups of women
[4]. The UK National Maternity Review, ‘Better Births’
[5], notes that a simple dichotomy of ‘high risk’ or ‘no
risk’ is too simplistic, and women are requesting more
detailed information about their risks. In this context,
defining all obese pregnant women as ‘high risk’ may
not always ensure provision of the most effective care
nor a choice of care pathway. We have previously sug-
gested that maternity care might benefit from a shift
away from the current focus on complications towards
the pursuit of uncomplicated pregnancy [6]. The identi-
fication of maternal characteristics associated with nor-
mal pregnancy outcomes in obese women and the
combining of these factors in a risk stratification algo-
rithm could help inform women’s decision-making with
regards to the management of their pregnancies as well
as the provision and allocation of resources for preg-
nancy care for obese women.
The aim of the present study is to identify factors in
the early second trimester associated with subsequent
uncomplicated pregnancy and birth in obese women and
to assess their predictive performance.
Methods
The UK Pregnancies Better Eating and Activity Trial
(UPBEAT; ISCRTN89971375) was a multicentre, rando-
mised controlled trial of a complex behavioural interven-
tion of diet and physical activity advice versus standard
antenatal care in obese pregnant women to prevent
GDM and delivery of large for gestational age infants. The
study involved eight centres located in London (three
centres), Bradford, Glasgow, Manchester, Newcastle, and
Sunderland. Regulatory approvals were obtained from the
UK research ethics committee (UK integrated research ap-
plication system, reference 09/H0802/5) and local research
and development departments in participating centres. All
women provided written informed consent prior to enter-
ing the study.
UPBEAT recruited 1555 obese women (BMI ≥ 30 kg/
m2), aged 16 years or older, and with a singleton preg-
nancy between 15+0 and 18+6 weeks’ gestation. Women
were recruited from March 2009 to June 2014. Exclusion
criteria were multiple pregnancy, current use of metfor-
min, unwilling or unable to provide written informed
consent, or underlying disorders (including a pre-
pregnancy diagnosis of essential hypertension, diabetes,
renal disease, systemic lupus erythematosus, antipho-
spholipid syndrome, sickle cell disease, thalassaemia,
coeliac disease, thyroid disease or current psychosis). Ex-
tensive data were collected on sociodemographic and
clinical characteristics, and anthropometric measures
and blood samples were also obtained. Women were
followed up at 27+0 to 28+6 and 34+0 to 35+6 weeks’ ges-
tation, at delivery and at 6 months postpartum [7, 8]. Ex-
cept for the UPBEAT behavioural intervention, routine
antenatal care according to UK and local practice was
provided to all women in the study.
For the purpose of this study, women with missing in-
formation for pregnancy outcomes were excluded. The
UPBEAT intervention was not associated with an effect
on the primary outcomes or any relevant pregnancy out-
come [8], and therefore the study population was treated
as a cohort for the purpose of this analysis [9].
Outcomes
The outcome of interest was an uncomplicated pregnancy
and birth defined in this study as a pregnancy without any
antenatal or labour complications following recruitment
at 15+0 to 18+6 weeks’ gestation. Antenatal complications
were late miscarriage, preterm birth (before 37 weeks’ ges-
tation), GDM, preeclampsia, hypertensive disorders of
pregnancy, antepartum haemorrhage, placental abruption,
venous thromboembolism, delivery of a small for gesta-
tional age infant (birthweight below the 10th customised
centile [10]) and stillbirth (after 20 weeks’ gestation).
Labour complications were instrumental vaginal birth,
emergency caesarean section, postpartum haemorrhage
(above 1000 mL), Apgar score < 7 at 5 minutes, neonatal
intensive care unit admission and neonatal death. Pre-
eclampsia was defined as blood pressure ≥ 140/90 mmHg
associated with proteinuria of ≥ 300 mg/24 h, or a spot
urine protein:creatinine ratio of ≥ 30 mg/mmol creatinine,
or urine dipstick protein ≥ 2+ [11], and a GDM diagnosis
was based on a 75 g oral glucose tolerance test (OGTT)
using the International Association of Diabetes and Preg-
nancy Study Groups (IADPSG) criteria [12]. Universal
OGTT was part of the study protocol but, where not per-
formed, a clinical diagnosis of GDM was used.
Potential predictors of uncomplicated pregnancy and birth
Factors from early pregnancy (15+0 to 18+6 weeks’ gesta-
tion) were selected on the basis of known associations
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with one or more pregnancy complications. The socio-
demographic characteristics and clinical factors explored
were maternal age, ethnicity (white, black, Asian or
other), adjusted index of multiple deprivation, BMI, par-
ity, previous history of GDM or preeclampsia, smoking,
history of threatened miscarriage in the index pregnancy,
systolic blood pressure (SBP) and maternal anthropom-
etry. Maternal anthropometric measures included were
mid-arm circumference and sum of skinfold thickness
(triceps, biceps, subscapular and suprailiac). Blood pres-
sure was recorded using the pregnancy validated Micro-
life BP3BT0-A blood pressure monitor (Microlife,
Widnau, Switzerland) and maternal skinfold thicknesses
(triceps, biceps, suprailiac and subscapular) were mea-
sured in triplicate, using Harpenden skinfold Calipers
(Holtain Ltd, Felin-y-Gigfran, Crosswell, UK) [13].
A total of 19 selected biomarkers measured in blood
samples obtained at 15+0 to 18+6 weeks’ gestation were
assessed. The biomarkers measured in blood samples
were markers of glucose homeostasis (haemoglobin A1c
(HbA1c), fructosamine, insulin and C-peptide), adipo-
kines (adiponectin and leptin), inflammatory and endo-
thelial markers (interleukin-6, high sensitivity C-reactive
protein, and t-PA antigen), lipids (triglycerides, total
cholesterol, LDL cholesterol and HDL cholesterol), liver-
associated markers (aspartate aminotransferase, alanine
aminotransferase, gamma-glutamyl transferase (gGT),
sex hormone binding globulin and ferritin) and vitamin
D. Analytical methods for these biomarkers are shown
in Additional file 1.
Statistical analysis
All participants with complete pregnancy outcome data
were included in the analysis. To ensure that the study
population was representative of the overall UPBEAT
participants we compared demographic characteristics
between women included and excluded from this ana-
lysis. Missing data on potential predictors were minimal
(< 2%), except for biomarkers, as blood samples were
not available for 27% of women (286/1409). Of those
with blood samples taken, biomarker missing data were
minimal (< 2%), except for HbA1c (5.7%; 59/1023). Bio-
markers were assessed for normality and variation with
gestational age. None of the biomarkers showed variation
with gestational age at measurement and biomarkers with
highly skewed distributions were transformed into log2
(insulin, C-peptide, adiponectin, leptin, interleukin-6, high
sensitivity C-reactive protein, t-PA antigen, triglycerides,
HDL cholesterol, aspartate aminotransferase, alanine ami-
notransferase, gGT, ferritin and vitamin D), so that odds
ratios (ORs) showed the effect associated with doubling
the concentration. Ethnicity was transformed into a binary
(white and non-white) variable for analysis to reduce the
degrees of freedom. The index of multiple deprivation was
categorised into fifths for a clearer interpretation. Con-
tinuous data were summarised by mean (standard devi-
ation) and categorical data reported as number
(percentage). Comparisons between groups were per-
formed using a t-test or χ2 test, as appropriate. Univari-
able logistic regression was used to estimate the effect size
for each factor. Clinical factors with a P value less than
0.05 in group comparison were included in multivariable
analyses. Biomarkers with a statistically significant asso-
ciation following Bonferroni correction for 19 tests (P <
0.0026) were included in multivariable analyses.
Backward stepwise logistic regression was then used to
identify factors that were independently associated with
uncomplicated pregnancies and birth [14]. One multi-
variable model was developed to include only clinical
factors, and a second model included both clinical fac-
tors and biomarkers. A sensitivity analysis was per-
formed to assess if the reduction in the sample size for
the assessment of biomarkers had any effect on the size
of the association between clinical factors and outcome.
The outcome of this study was a normal event instead of
an adverse outcome, factors with an OR smaller than
one were considered predictors of an adverse outcome,
whereas those with an OR greater than one were consid-
ered to predict increased likelihood of an uncomplicated
pregnancy. The overall accuracy of the final multivari-
able model to discriminate between uncomplicated and
complicated pregnancy was assessed using the area
under the receiver operating characteristic curve
(AUROC). Internal cross-validation using a 10-fold split
in the dataset was performed [15]. Calibration was
assessed by comparing observed to predicted levels of
uncomplicated pregnancy and birth within tenths of pre-
dicted risk and a Hosmer–Lemeshow test was per-
formed. Women were then divided into fifths of
predicted risk and pregnancy outcomes were compared
between the fifths. Finally, the upper fifth of predicted
levels of uncomplicated pregnancy and birth was consid-
ered a positive screening group and diagnostic test per-
formance was assessed (sensitivity, specificity, positive
predictive value and negative predictive value). All statis-
tical analyses were performed using Stata software, ver-
sion 14.1 (StataCorp, College Station, Texas). This study
was reported in accordance with the TRIPOD guideline
for reporting the development of multivariable predic-
tion models [16].
Results
The UPBEAT trial recruited 1555 obese women between
15+0 and 18+6 weeks’ gestation. In this analysis, the study
population comprised 1409 women with complete out-
come data (Fig. 1) and there were no obvious differences
in demographic characteristics between our study popu-
lation and UPBEAT participants excluded from this
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analysis. Additional file 2 describes these comparisons.
The prevalence of uncomplicated pregnancy and birth in
the study population was 36% (505/1409).
Amongst women with complications, 38% (342/904)
had antenatal complications alone, 32% (287/904) had
labour complications alone and 30% (275/904) experi-
enced both. Women who experienced both antenatal
and labour complications accounted for 20% (275/1409)
of the whole study population (Additional file 3 shows
this distribution). The prevalence of each pregnancy
complication is described in Table 1. GDM was the lead-
ing antenatal complication and emergency caesarean
section was the most prevalent labour complication.
The sociodemographic characteristics of women with
and without complications in pregnancy are described in
Table 2, and the descriptive statistics for potential pre-
dictors of uncomplicated pregnancy and birth are shown
in Additional file 4.
In univariable analyses, multiparity was associated with
increased odds of an uncomplicated pregnancy and
birth, and factors associated with a reduced odds were
higher maternal age, SBP, BMI, mid-arm circumference
and sum of skinfolds (Table 3). A previous history of ei-
ther GDM or preeclampsia was also associated with re-
duced odds of uncomplicated pregnancy and birth.
Higher concentrations of adiponectin were associated
with greater odds of uncomplicated pregnancy and birth,
while reduced odds were observed for higher HbA1c, in-
sulin, sex hormone binding globulin and gGT. In multi-
variable analysis, multiparity, SBP, adiponectin and
HbA1c were independently associated with uncompli-
cated pregnancy and birth (Table 3). Using these factors
from multivariable analysis, the algorithm achieved an
AUROC of 0.73 (0.69–0.76) (Table 3). Model perform-
ance was confirmed by internal validation with an
AUROC of 0.72 (0.68–0.76). The model also had good
calibration as demonstrated by the similarity of pre-
dicted and observed proportions of uncomplicated preg-
nancies and births across tenths of predicted risk (Fig. 2;
Hosmer–Lemeshow P = 0.54).
Fig. 1 Study population
Table 1 Prevalence of each pregnancy complication
N (n = 1409) Percent
Antenatal complications
Miscarriage 8 0.6
Preterm birth 77 5.5
Gestational diabetes 334 23.7
Preeclampsia 53 3.8
Other hypertensive disorders 83 5.9
Antepartum haemorrhage 54 3.8
Placental abruption 9 0.6
Venous thromboembolism 4 0.3
Small for gestational age 162 11.5
Stillbirth 7 0.5
Labour complications
Instrumental delivery 165 11.7
Emergency caesarean section 237 16.8
Postpartum haemorrhage 186 13.2
Apgar < 7 at 5 min 28 2.0
Neonatal intensive care 113 8.0
Neonatal death 4 0.3
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Women were then divided in fifths of predicted risk
and the prevalence of each adverse outcome in the fifths
is described in Table 4. With an increasing predicted
chance of uncomplicated pregnancies and birth, a trend
of reduced prevalence of antenatal (preterm delivery,
gestational diabetes, preeclampsia and other hyperten-
sive disorders) and labour complications (caesarean sec-
tion and postpartum haemorrhage) were observed.
Sensitivity, specificity, and positive and negative predict-
ive value of the upper (5th) fifth (compared with all
other women) for an uncomplicated pregnancy and birth
were 38% (32–43%), 89% (86–91%), 63% (55–70%) and
74% (71–77%), respectively. Positive likelihood ratio and
negative likelihood ratio were also calculated (3.3 and
0.7, respectively).
The model including only clinical factors (AUROC of
0.68, 0.65–0.71) was also used to explore the prevalence
of each adverse outcome in each fifth of predicted risk
(Table 5). Diagnostic test performance was also calcu-
lated for this model. Sensitivity, specificity, and positive
and negative predictive values of the upper fifth were
31% (27–36%), 86% (84–89%), 56% (50–62%) and 69%
(66–72%), respectively. The positive and negative likeli-
hood ratios were 2.3 and 0.8, respectively. Additional file
5 describes the fifths of predicted risk for an alternative
model including clinical factors and HbA1c (AUROC
0.71, 0.66–0.75). This post-hoc analysis was performed
as HbA1c is readily available in clinical practice in most
countries, while adiponectin is more often available in
research settings. Sensitivity, specificity, and positive and
Table 2 Sociodemographic characteristics in pregnancies with
and without complications in pregnancy and/or birth
Complicated
pregnancy,
Mean (SD) or n (%)
Uncomplicated
pregnancy,
Mean (SD) or n (%)
Age 30.6 (5.4) 30.0 (5.7)
Body mass index 36.6 (5.2) 35.9 (4.1)
Ethnicity
White 567/904 (62.7) 319/505 (63.2)
Black 224/904 (24.8) 132/505 (26.1)
Asian 55/904 (6.1) 31/505 (6.1)
Other 58/904 (6.4) 23/505 (4.6)
Multiparous 416/904 (46.0) 370/505 (73.3)
Previous history of GDM 22/416 (5.3) 6/370 (1.6)
Previous history of PE 37/416 (8.9) 25/370 (6.8)
IMD fifths
1 (least deprived) 33/899 (3.7) 19/504 (3.8)
2 62/899 (6.9) 32/504 (6.4)
3 95/899 (10.6) 61/504 (12.1)
4 316/899 (35.2) 164/504 (32.5)
5 (most deprived) 393/899 (43.7) 228/504 (45.2)
Current smoker 66/904 (7.3) 32/505 (6.3)
GDM gestational diabetes mellitus, IMD index of multiple deprivation,
PE preeclampsia
Table 3 Factors associated with uncomplicated pregnancies and birth, and their predictive performance
Univariablea,
OR (95% CI)
Multivariable (Clinical factors only),
OR (95% CI), n = 1370
Multivariable (All factors),
OR (95% CI), n = 907
Maternal age (per 5 year), n = 1409 0.90 (0.82–1.00) 0.79 (0.71–0.88) 0.81 (0.71–0.93)
Multiparous, n = 1409 3.22 (2.54–4.07) 3.54 (2.75–4.55) 4.23 (3.04–5.88)
Previous history of GDM or PE, n = 786 0.58 (0.36–0.91)
SBP (per 10 mmHg), n = 1387 0.77 (0.69–0.85) 0.82 (0.73–0.91) 0.84 (0.73–0.97)
BMI (per 5 kg/m2), n = 1409 0.84 (0.74–0.94) 0.85 (0.74–0.97)
Mid-arm circumference (per 1 cm) n = 1398 0.96 (0.94–0.99)
Sum of skinfolds (per 1 cm), n = 1390 0.94 (0.91–0.98)
Biomarkers
HbA1c (per 1 mmol/mol), n = 949 0.90 (0.87–0.94) 0.90 (0.86–0.94)
Insulin (per doubling, log2 of mU/L), n = 1017 0.86 (0.78–0.94)
Adiponectin (per doubling, log2 of μg/mL), n = 1013 1.34 (1.16–1.56) 1.40 (1.18–1.66)
gGT (per doubling, log2 of U/L), n = 1015 0.78 (0.67–0.89)
SHBG (per 1 nmol/L), n = 1004 1.00 (1.00–1.00)
AUROC 0.69 (0.66–0.71) 0.73 (0.69–0.76)
Internal validation AUROC 0.68 (0.65–0.71) 0.72 (0.68–0.76)
aIn univariable analyses numbers vary depending on missing data and are given in the first column
AUROC area under the receiver operating characteristic curve, BMI body mass index, GDM gestational diabetes mellitus, gGT gamma-glutamyl transferase, HbA1c
haemoglobin A1c, PE preeclampsia, SBP systolic blood pressure, SHBG sex hormone binding globulin
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negative predictive values of the upper fifth using this al-
ternative model were 33% (29–40%), 87% (84–90%), 57%
(49–64%) and 72% (69–76%), respectively.
In sensitivity analyses, we found that the point estimates
for the associations of clinical predictors with uncomplicated
pregnancy and birth were broadly similar in the group with
maximal data and those who were excluded because of
missing data. Additional file 6 describes these results.
Discussion
Over one-third of this contemporary, multi-ethnic, inner
city population of obese pregnant women had an un-
complicated pregnancy and birth. Nevertheless, this also
highlights the extent to which obesity is an important
risk factor for pregnancy complications. Combining clin-
ical factors and biomarkers, we identified five independ-
ent predictors in early pregnancy (at 15+0 to 18+6 weeks’
gestation) that were associated with an uncomplicated
Fig. 2 Calibration of the full prediction model for uncomplicated
pregnancies in obese women
Table 4 Pregnancy outcomes according to predicted chance in fifths of uncomplicated pregnancy and birth using the full model
Least likely to have
an uncomplicated
pregnancy and birth
Most likely to have
an uncomplicated
pregnancy and birth
1st fifth
(n = 181)
2nd fifth
(n = 181)
3rd fifth
(n = 182)
4th fifth
(n = 181)
5th fifth
(n = 182)
P value
Uncomplicated pregnancy (%) 22 (12.2) 34 (18.8) 58 (31.9) 75 (41.4) 114 (62.6) < 0.001
Antenatal outcomes (%)
Miscarriagea 2 (1.1) 2 (1.1) 1 (0.5) 3 (1.7) 0 (0) 0.51
Preterm delivery 11 (6.1) 16 (8.9) 6 (3.3) 7 (3.9) 5 (2.7) 0.04
Gestational diabetes 77 (43) 50 (27.9) 57 (31.5) 35 (19.7) 29 (15.9) < 0.001
Preeclampsia 12 (6.7) 13 (7.3) 6 (3.3) 3 (1.7) 6 (3.3) 0.04
Other hypertensive disorders 16 (8.9) 12 (6.7) 13 (7.2) 9 (5.1) 2 (1.1) 0.02
Antepartum haemorrhage 11 (6.1) 4 (2.2) 8 (4.4) 12 (6.7) 3 (1.6) 0.06
Placental abruption 2 (1.1) 0 (0) 1 (0.6) 1 (0.6) 2 (1.1) 0.68
Venous thromboembolism 0 (0) 1 (0.6) 0 (0) 0 (0) 0 (0) 0.40
Small for gestational age 26 (14.5) 31 (17.3) 18 (9.9) 18 (10.1) 18 (9.9) 0.10
Large for gestational age 16 (8.9) 11 (6.1) 18 (9.9) 17 (9.6) 18 (9.9) 0.69
Stillbirth 2 (1.1) 0 (0) 1 (0.6) 1 (0.6) 1 (0.5) 0.73
Labour outcomes (%)
Induction of labour 95 (52.0) 76 (42.5) 60 (33.1) 45 (25.3) 51 (28.0) < 0.001
Elective caesarean section 41 (22.9) 22 (12.3) 34 (18.8) 41 (23.0) 44 (24.2) 0.03
Mode of delivery (in labour)
Spontaneous vaginal 56 (40.6) 76 (48.4) 94 (63.9) 105 (76.6) 127 (92.0) < 0.001
Instrumental delivery 27 (19.6) 35 (22.3) 21 (14.3) 16 (11.7) 3 (2.2) < 0.001
Emergency CS 55 (39.9) 46 (29.3) 32 (21.8) 16 (11.7) 8 (5.8) < 0.001
Postpartum haemorrhage 44 (24.6) 28 (15.6) 27 (14.9) 20 (11.2) 16 (8.8) < 0.001
Apgar < 7 at 5 min 6 (3.4) 4 (2.2) 2 (1.1) 4 (2.2) 3 (1.6) 0.66
NICU admission 19 (10.6) 20 (11.2) 15 (8.3) 12 (6.7) 10 (5.5) 0.24
Neonatal death 1 (0.6) 1 (0.6) 0 (0) 0 (0) 1 (0.5) 0.74
aWomen with miscarriage were not included in the analysis of other outcomes
CS caesarean section, NICU neonatal intensive care unit
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pregnancy and birth, namely multiparity, lower maternal
age, SBP and HbA1c levels, and higher adiponectin levels.
In combination, these achieved an AUROC of 0.72 (0.68–
0.76) for the prediction of an uncomplicated pregnancy and
birth. The use of the upper fifth of predicted risk of uncom-
plicated pregnancy and birth as the screen positive group
provided a sensitivity of 38% and a specificity of 89%.
When considering the individual pregnancy complica-
tions, the most prevalent during the antenatal period
and labour were GDM and emergency caesarean section,
respectively. We found that the prevalence of GDM, pre-
eclampsia and other hypertensive disorders, preterm
birth, and postpartum haemorrhage decreased and spon-
taneous vaginal delivery increased across the five groups
defined by increasing predicted chance of uncomplicated
pregnancy and birth. There was no strong evidence of any
difference in miscarriage, antepartum haemorrhage, pla-
cental abruption, venous thrombus-embolism, stillbirth,
low Apgar score, admission to neonatal intensive care or
neonatal death across the five groups, but the numbers in
each were few. In general, however, the prevalence of
these adverse events was lowest in the group with highest
prediction of uncomplicated pregnancy and birth. This
suggests that our approach of using one composite out-
come is appropriate as those women predicted to have un-
complicated pregnancy and birth were also those shown
to have a lower risk for individual adverse outcomes.
To our knowledge, there has been no previous study ad-
dressing a composite outcome of uncomplicated pregnancy
and birth in obese women. Our previous study explored the
factors associated with uncomplicated pregnancy amongst
nulliparous women of any BMI [6]. Approximately 61% of
nulliparous women unselected for BMI had uncomplicated
pregnancies, compared to 38% in the present cohort of
women with obesity. Although we would expect lower rates
of uncomplicated pregnancy and birth outcomes in obese
Table 5 Pregnancy outcomes according to predicted chance in fifths of uncomplicated pregnancy and birth using the clinical model
Least likely to have
an uncomplicated
pregnancy and birth
Most likely to have
an uncomplicated
pregnancy and birth
1st fifth
(n = 181)
2nd fifth
(n = 181)
3rd fifth
(n = 182)
4th fifth
(n = 181)
5th fifth
(n = 182)
P value
Uncomplicated pregnancy (%) 47 (17.2) 67 (24.5) 98 (35.8) 126 (46) 154 (56.2) < 0.001
Antenatal outcomes (%)
Miscarriagea 2 (0.7) 1 (0.4) 2 (0.7) 2 (0.7) 1 (0.4) 0.94
Preterm delivery 13 (4.8) 23 (8.4) 8 (2.9) 17 (6.3) 14 (5.1) 0.07
Gestational diabetes 82 (30.1) 59 (21.6) 73 (26.8) 71 (26.1) 39 (14.3) < 0.001
Preeclampsia 16 (5.9) 17 (6.2) 8 (2.9) 6 (2.2) 4 (1.5) 0.006
Other hypertensive disorders 37 (13.6) 9 (3.3) 19 (7.0) 12 (4.4) 5 (1.8) < 0.001
Antepartum haemorrhage 15 (5.5) 8 (2.9) 9 (3.3) 14 (5.1) 7 (2.6) 0.26
Placental abruption 2 (0.7) 2 (0.7) 2 (0.7) 3 (1.1) 0 (0) 0.61
Venous thromboembolism 2 (0.7) 1 (0.4) 0 (0) 0 (0) 0 (0) 0.25
Small for gestational age 34 (12.5) 43 (15.8) 27 (9.9) 27 (9.9) 27 (9.9) 0.13
Large for gestational age 22 (8.1) 19 (7.0) 25 (9.2) 30 (11.0) 24 (8.8) 0.55
Stillbirth 2 (0.7) 2 (0.7) 2 (0.7) 1 (0.4) 0 (0) 0.68
Labour outcomes (%)
Induction of labour 145 (53.3) 107 (39.2) 92 (33.8) 72 (26.5) 64 (23.4) < 0.001
Elective caesarean section 47 (17.3) 33 (12.1) 64 (23.5) 70 (25.7) 46 (16.8) < 0.001
Mode of delivery (in labour)
Spontaneous vaginal 88 (39.1) 113 (47.1) 136 (65.4) 169 (83.7) 204 (89.9) < 0.001
Instrumental delivery 55 (24.4) 59 (24.6) 25 (12.0) 14 (6.9) 7 (3.1) < 0.001
Emergency CS 82 (36.4) 68 (28.3) 47 (22.6) 19 (9.4) 16 (7.0) < 0.001
Postpartum haemorrhage 57 (21) 39 (14.3) 32 (11.8) 27 (9.9) 23 (8.4) < 0.001
Apgar < 7 at 5 min 10 (3.7) 5 (1.8) 5 (1.8) 5 (1.8) 2 (0.7) 0.18
NICU admission 29 (10.7) 23 (8.4) 19 (7.0) 22 (8.1) 18 (6.6) 0.45
Neonatal death 0 (0) 1 (0.4) 0 (0) 3 (1.1) 0 (0) 0.07
aWomen with miscarriage were not included in the analysis of other outcomes
CS caesarean section, NICU neonatal intensive care unit
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women, this difference may be partly attributed to the
definition of uncomplicated pregnancy and birth, which
varied between studies (instrumental delivery and emer-
gency caesarean section were only considered a pregnancy
complication in the present study). Despite the different
populations, lower maternal age, SBP and BMI were asso-
ciated with uncomplicated pregnancy in both studies.
Despite being a widely recognised major risk factor for
pregnancy complications [1], the recent World Health
Organization recommendations on antenatal care as well
as current antenatal guidelines in the UK do not provide
specific recommendations for the management of preg-
nancy in obese women [17, 18]. The American College
of Obstetrics and Gynaecology has published a relevant
practice bulletin, but this provides recommendations for
all obese women and does not offer stratification of care
in this large group [19]. We have shown that it is possible
to identify different risk groups amongst obese women,
with good discrimination and calibration. Ultimately, we
hope that this approach might help improve the manage-
ment of obese pregnant women. Women with the highest
prediction of uncomplicated pregnancy and birth (those
in the upper fifth) had similar levels of risk of most com-
plications to those seen in an unselected obstetric popu-
lation [12, 20–22], and might benefit from different
pathways of care compared to all obese women. In this se-
lected group of women with obesity, the observed preva-
lence of GDM (16%) was similar to the incidence
described in the HAPO study (unselected population)
when using the IADPSG criteria (16%) [12] and the preva-
lence of preeclampsia (3%) was similar to that previously
reported in lean women (3%) and lower than previously
observed in women with obesity (9%) [21]. Finally, the
prevalence of small for gestational age infants (10%) was
similar to an unselected population (9–12%) [20].
Since obese women are currently defined as high risk,
a higher AUROC for uncomplicated pregnancy than that
achieved by the full model (0.72, 0.68–0.76) in this
group might be desirable. This also applies to the predic-
tion tool based on clinical factors (AUROC of 0.68,
0.65–0.71). We therefore recommend that the effective-
ness of any alternative pathway of care based on these
prediction tools should be fully evaluated prior to imple-
mentation in clinical practice. Inclusion of other relevant
variables, for example, previous obstetric history, weight
change from pre-pregnancy to early second trimester or
additional biomarkers, may further improve the accuracy
of these models. Further studies should also focus on
identifying possible causal mechanisms (i.e. biomarkers
of good glycaemic control and lower insulin resistance)
contributing to uncomplicated pregnancy and birth,
which could be amenable to targeted interventions.
Our results have immediate relevance to the choice of
place of birth. According to NICE, all women with a
BMI ≥ 35 kg/m2 should receive recommendation to de-
liver in an obstetric unit [23]. However, some high risk
women still choose to receive care in low risk settings,
and therefore clearer direction is needed for shared
decision-making. In the Birthplace study, 35% of ‘higher
risk’ women who planned a home birth were obese
(BMI ≥ 30 kg/m2) [24]. In our study, the rate of spontan-
eous vaginal delivery in obese women in labour with a
BMI ≥ 35 kg/m2 was 62% (57–67%), similar to that in
women with a BMI of 30–35 kg/m2 (66%, 61–71%). Im-
portantly, women identified as most likely to have an
uncomplicated pregnancy and birth (upper fifth) by our
prediction model had a higher rate of spontaneous vagi-
nal delivery of 92% (87–97%) following onset of labour.
This figure was markedly similar (90%, 86–94%) in the
simpler model including clinical factors alone. In com-
mon with our findings, the Birthplace study also identi-
fied a subgroup of lower risk women with a BMI ≥
35 kg/m2 in which the risk for obstetric interventions or
maternal adverse outcomes was lower than in nullipar-
ous women of normal BMI (21% vs. 53%) [25]. Together,
these observations suggest that the current NICE guide-
line could be modified.
It is generally accepted that obese women should be
offered a 75 g OGTT between 24 and 28 weeks’ gesta-
tion. Lower risk obese women in this study had a GDM
prevalence of 16%, similar to the prevalence in an unse-
lected population with the same IADPSG diagnostic cri-
teria [12]. Therefore, it is difficult to suggest a different
screening approach for GDM that would be widely ac-
cepted. However, the women least likely to have an un-
complicated pregnancy and birth had a GDM prevalence
of 43%. These women are likely to benefit from early
management or increased surveillance (i.e. prophylactic
interventions or early pregnancy OGTT) [26]. Similarly,
higher preeclampsia rates were observed for women
least likely to have an uncomplicated pregnancy and
birth; therefore, these women may benefit from add-
itional blood pressure measurements.
A key strength of this study lies in the prospective col-
lection of detailed clinical, anthropometric and bio-
marker data related to obesity with contemporaneous
data monitoring across all sites. Another strength lies in
the assessment of uncomplicated pregnancy and birth,
and in the principle of a prediction tool applicable to all
pregnancies in obese women rather than one for each
outcome (i.e. GDM, preeclampsia, fetal growth restric-
tion). This novel concept simplifies stratification in
obese women who are at increased risk of multiple ad-
verse outcomes. A limitation was the number of women
without biomarker data (286/1409, 27%). To explore po-
tential selection bias, we assessed the effect size of each
clinical factor in the whole study population and in the
restricted study cohort (with available biomarkers);
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similar effect sizes were observed in both samples. A
‘healthy cohort’ effect cannot be excluded; obese women
who took part in UPBEAT may have been healthier than
the general obese pregnant population, and our predic-
tion model performance would not be generalisable.
However, we consider this unlikely as UPBEAT partici-
pants had maternal demographic characteristics usually
associated with the poorest pregnancy outcomes, being
on average 10 months older and with a BMI 0.7 kg/m2
higher compared to women who declined participation
[8]. Other limitations include the low prevalence of
some outcomes, such as stillbirth or neonatal death,
leading to reduced statistical power. We also acknow-
ledge that external independent validation of our predic-
tion tool is necessary.
Conclusion
Approximately one-third of the obese women studied
had an uncomplicated pregnancy and birth. We have
shown that risk stratification could be achieved by a
combination of clinical factors and biomarkers. Stratifi-
cation of risk for an uncomplicated pregnancy is an in-
novative approach to the management of obese pregnant
women, with the potential to improve clinical manage-
ment and the choices for women as well as to ensure ef-
ficient resource allocation. Further studies are needed to
explore alternative pathways of care for the sub-groups
of obese women who differ according to risk profile for
uncomplicated pregnancy and birth.
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